secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLARGO, INC. (BLGO)
CIK:        0000880242
Form:       8-K
Filed at:   2022-04-04T23:59:59+00:00
Accession:  0001437749-22-008195
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLargo 2021 revenue $2.53M (+4%), net loss down 29% to $6.9M, debt cut to $0.68M
--------------------------------------------------------------------------------

- Revenue of $2,531,000 for FY2021, a 4% increase from 2020; Q4 revenue $784,000 (+10% QoQ).
- Net loss reduced 29% to $6.9M, including $1.9M non-cash option expense and $342K impairment.
- Total debt slashed from $2.9M to $681K; total liabilities down from $5.2M to $2.1M.
- AEC PFAS treatment passed tests with municipality and federal agency; Garratt-Callahan MLD prototype completed.
- Ikigai partnership for pet odor product exceeds initial projections; Clyra's Bioclynse secures two hospital customers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/880242/000143774922008195/0001437749-22-008195-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/880242/000143774922008195/blgo20220404_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-008195

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer